R&D Spending Showdown: Eli Lilly and Company vs ACADIA Pharmaceuticals Inc.

Eli Lilly vs. ACADIA: A Decade of R&D Investment

__timestampACADIA Pharmaceuticals Inc.Eli Lilly and Company
Wednesday, January 1, 2014606020004733600000
Thursday, January 1, 2015738690004796400000
Friday, January 1, 2016992840005243900000
Sunday, January 1, 20171491890005281800000
Monday, January 1, 20181871630005051200000
Tuesday, January 1, 20192403850005595000000
Wednesday, January 1, 20203191300006085700000
Friday, January 1, 20212394150007025900000
Saturday, January 1, 20223615750007190800000
Sunday, January 1, 20233516190009313400000
Monday, January 1, 202414271000000
Loading chart...

Igniting the spark of knowledge

R&D Spending: A Tale of Two Companies

In the competitive world of pharmaceuticals, research and development (R&D) is the lifeblood of innovation. Over the past decade, Eli Lilly and Company and ACADIA Pharmaceuticals Inc. have showcased contrasting R&D investment strategies. Eli Lilly, a titan in the industry, has consistently invested heavily, with R&D expenses peaking at approximately $9.3 billion in 2023, marking a 97% increase from 2014. In contrast, ACADIA Pharmaceuticals, a smaller player, has seen its R&D spending grow by nearly 480% over the same period, reaching around $352 million in 2023. This stark difference highlights the varied approaches companies take to fuel innovation. While Eli Lilly's vast resources allow for substantial investment, ACADIA's growth trajectory underscores its commitment to expanding its research capabilities. As the pharmaceutical landscape evolves, these investment patterns will play a crucial role in shaping the future of drug development.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025